A Phase 1a/1b Study of ELVN-001 for the Treatment Chronic Myeloid Leukemia
← catalyst calendarNCT05304377 · readout ≤ 499 d
Sponsored by Enliven Therapeutics (industry) · ELVN — their whole pipeline →.
Phase
Phase 1
Status
Recruiting
Study type
Interventional
Design
Non randomized · None · Treatment
Enrollment
250estimated
Sites
45
Countries
Australia, Belgium, Canada +11
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2022-05-22 | actual | When the study began enrolling |
| Primary completion | Dec 2027 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | Dec 2027 | estimated | The whole study's end, after follow-up |
| First posted | 2022-03-31 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-04-01 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- Chronic Myeloid Leukemia
- Chronic Phase Chronic Myeloid Leukemia, BCR-ABL1 Positive
- Cml
Intervention
- Drug: ELVN-001
Primary outcomes
what the primary-completion date above is the date OFPhase 1a: Incidence of dose limiting toxicities
measured 28 days
Phase 1a: Incidence of adverse events (AEs)
measured up to 28 days
Phase 1a: Incidence of clinically significant laboratory abnormalities
measured up to 28 days
Phase 1a: Incidence of clinically significant ECG abnormalities
measured up to 28 days
Phase 1b: Incidence of adverse events
measured up to 3 years
Phase 1b: Incidence of clinically significant laboratory abnormalities
measured up to 3 years
Phase 1b: Incidence of clinically significant ECG abnormalities
measured up to 3 years
Permalink · ELVN's whole pipeline · Catalyst calendar · Every registered study · What changed